Certara reports Q3 adjusted EPS 11c, consensus 11c

Reports Q3 revenue $85.6M, consensus $86.25M. “During the third quarter we saw customer demand stabilize across the Certara platform. We continue to see strong interest from customers in Biosimulation, while our Regulatory business returned to growth in bookings,” said William Feehery, CEO. “Customer activity improved through the quarter and we believe the outlook for biosimulation remains strong. Our newly aligned commercial and services teams are showing signs of initial success, which we intend to build upon as we head into 2024.”